Guangrong Zheng, Ph.D.

Guangrong Zheng

Associate Professor

Medicinal Chemistry

OFFICE: Basic Science Building, BG-022C

EMAIL: zhengg@cop.ufl.edu

PHONE: 352-273-9043

CV: Link to CV

 

Guangrong Zheng, Ph.D., is an associate professor in the department of medicinal chemistry at the University of Florida College of Pharmacy. He received his B.S. in medicinal chemistry from Fudan University and his Ph.D. in synthetic organic chemistry from Shanghai Institute of Materia Medica. He then completed his postdoc training in drug design and discovery at the University of Kentucky College of Pharmacy. Before he joined UF in March 2018, he was a faculty member at University of Arkansas for Medical Sciences College of Pharmacy.

Affiliation

  • UF Cancer Center
  • American Association of Pharmaceutical Scientists (AAPS)
  • American Chemical Society (ACS), Medicinal Chemistry and Organic Chemistry Divisions

Research Interests

Dr. Zheng’s lab focuses on the design, synthesis and structure-activity relationship study of both synthetically derived and natural product-based compounds for potential therapeutic uses or as molecular probes for biochemical/pharmacological research. His research also involves the development of efficient synthetic methodologies and strategies to facilitate the rapid construction of compound libraries. Ongoing projects in his lab include 1) development of small molecules that can induce targeted protein degradation as potential treatments for cancer; 2) development of senolytic agents, small molecules that can selectively kill senescent cells, as potential treatments for age-related diseases; and 3) development of radioprotective agents to improve the outcome of cancer radiotherapy or as radiation counter-measure agents.

Select Publications

Hoang, N.; Zhang, X.; Zhang C.; Vo, V.; Leng, F.; Saxena, L.; Yin, F.; Lu, F.; Zheng,G.; Bhowmik, P.; Zhang, H. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma cells by downregulating Sox2 expression. Bioorg.Med. Chem. 2018, In Press.

Lee, N-R.; Zheng, G.; Crooks, P. A.; Bardo, M. T.; Dwoskin, L. P. Novel scaffold for lead compounds to treat methamphetamine use disorders. AAPS J. 2018, 20, 1-10.

Moon, S. H.; Zhang, X.; Zheng,G.; Meeker, D. G.; Smeltzer, M. S.; Huang, E. Novel linear lipopeptide paenipeptins with potential for eradicating biofilm and sensitizing Gram-negative bacteria to rifampicin and clarithromycin. J. Med. Chem.2017, 60, 9630-9640.

Nickell, J. R.; Siripurapu, K. B.; Horton, D. B.; Zheng, G.; Crooks, P. A.; Dwoskin, L. P.*GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur. J. Pharmacol. 2017, 795, 143-149.

Wang, Y.; Chang, J.; Liu X.; Zhang, X.; Zhang, S.; Zhang, X.; Zhou, D.; Zheng, G.Discovery of piperlongumine as a novel lead for the development of senolytic agents. Aging. 2016, 8, 2915-2926.

Liu, X.; Gujarathi, S.; Zhang, X.; Shao, L.; Boerma, M.; Compadre, C. M.; Crooks, P. A.; Hauer-Jensen, M.; Zhou, D.; Zheng, G.Synthesis of (2R,8′S,3′E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol. Tetrahedron. 2016, 72, 4001-4006.

Bommagani, S.; Lee, N. R.; Zhang, X.; Dwoskin, L. P.; Zheng, G.Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one. Tetrahedron Lett. 2015, 56, 6472-6474. PMCID: PMC4671082.

Gujarathi, S.; Zheng, G. AgSbF6-catalyzed efficient propargylation/cycloisomerization tandem reaction for the synthesis of fully substituted furans and new insights into the reaction mechanism. Tetrahedron. 2015,71,6183-6188.

Zheng, G.; Smith, A.; Huang, X.; Subramanian, K.; Siripurapu, K.; Deaciuc, A.; Zhan, C.-G. Dwoskin, L. P. Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. J. Med. Chem. 2013, 56, 1693-1703. PMCID: PMC3676450.